Literature DB >> 1748555

Correlation of chromatic, spatial, and temporal sensitivity in optic nerve disease.

S S Grigsby1, A J Vingrys, S C Benes, P E King-Smith.   

Abstract

Spearman rank-order correlations (R) were made between the color-mixture threshold, spatial contrast sensitivity, and flicker sensitivity measurements of 38 patients with a variety of optic nerve disorders. Patients had to satisfy the following criteria: greater than 0.5 log unit loss of chromatic or achromatic sensitivity (compared to age-matched normals), central fixation, no congenital color defects, and no ocular media abnormalities. The results of the analysis show a significant correlation between selective losses of high spatial frequency sensitivity (relative to low) and selective losses of red/green and blue/yellow sensitivities [R = -0.680 (P less than 0.001) and R = -0.439 (P less than 0.01), respectively]. A mild correlation was found between selective spatial and selective temporal losses [r = -0.399 (P less than 0.05)] (ie, low temporal frequency losses correlate with high spatial frequency losses and vice versa). A stronger correlation was found between selective red/green and selective blue/yellow sensitivity losses [R = 0.657 (P less than 0.001)]. No correlation was found between selective temporal losses and selective chromatic losses. These findings can be explained in terms of differential losses of three types of fibers: (1) fibers that are particularly sensitive to red/green color, high spatial and low temporal frequencies; (2) fibers signalling blue/yellow color; and (3) fibers that are relatively sensitive to high temporal frequencies and low spatial frequencies.

Entities:  

Mesh:

Year:  1991        PMID: 1748555

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Human vision with a lesion of the parvocellular pathway: an optic neuritis model for selective contrast sensitivity deficits with severe loss of midget ganglion cell function.

Authors:  Amal M Al-Hashmi; Daniel J Kramer; Kathy T Mullen
Journal:  Exp Brain Res       Date:  2011-10-18       Impact factor: 1.972

2.  Functional loss in the magnocellular and parvocellular pathways in patients with optic neuritis.

Authors:  Dingcai Cao; Andrew J Zele; Joel Pokorny; David Y Lee; Leonard V Messner; Christopher Diehl; Susan Ksiazek
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-17       Impact factor: 4.799

3.  Prospective, cross-sectional study, demonstrating efficacy of blue fixation target while recording Pattern Visual Evoked Potential in optic neuropathy.

Authors:  Ajoy Vincent; Rohit Shetty; Mathew Kurian; Bhujang K Shetty
Journal:  Doc Ophthalmol       Date:  2009-06-10       Impact factor: 2.379

4.  A simple computer program to quantify red desaturation in patients with optic neuritis.

Authors:  Yehoshua Almog; Raz Gepstein; Arie Y Nemet
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-06-19       Impact factor: 3.117

5.  A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy.

Authors:  Thomas Klopstock; Patrick Yu-Wai-Man; Konstantinos Dimitriadis; Jacinthe Rouleau; Suzette Heck; Maura Bailie; Alaa Atawan; Sandip Chattopadhyay; Marion Schubert; Aylin Garip; Marcus Kernt; Diana Petraki; Christian Rummey; Mika Leinonen; Günther Metz; Philip G Griffiths; Thomas Meier; Patrick F Chinnery
Journal:  Brain       Date:  2011-07-25       Impact factor: 13.501

6.  Validation of a Tablet as a Tangent Perimeter.

Authors:  Algis J Vingrys; Jessica K Healey; Sheryl Liew; Veera Saharinen; Michael Tran; William Wu; George Y X Kong
Journal:  Transl Vis Sci Technol       Date:  2016-07-14       Impact factor: 3.283

7.  Effects of idebenone on color vision in patients with leber hereditary optic neuropathy.

Authors:  Guenther Rudolph; Konstantinos Dimitriadis; Boriana Büchner; Suzette Heck; Jasmina Al-Tamami; Florian Seidensticker; Christian Rummey; Mika Leinonen; Thomas Meier; Thomas Klopstock
Journal:  J Neuroophthalmol       Date:  2013-03       Impact factor: 3.042

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.